Prescription medication · Echinocandin Antifungal
micafungin
Also sold as Mycamine. Micafungin treats several types of Candida infections.
Data updated 2026-05-15
- 4,779
- FDA reportsLightly reported
- 8
- InteractionsFew interactions
- 1
- Recall record
What the data shows
micafungin (Mycamine) is a prescription Echinocandin Antifungal, reported less often than most tracked drugs (4,779 FDA reports), with 8 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
micafungin (Mycamine) is a prescription Echinocandin Antifungal. Micafungin treats several types of Candida infections.
Micafungin is an antifungal medicine. It treats certain Candida infections in adults and children.
Verify with FDA → · CMS NADAC pricing →
What it does
Micafungin treats several types of Candida infections.
Common side effects
Diarrhea, Nausea, Vomiting
Key warnings
Micafungin can cause serious allergic reactions, including shock.
The sections below are summarized in plain English from micafungin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Micafungin stops the growth of Candida by blocking a key part of its cell wall. This weakens the fungus and allows your body to fight the infection. It targets a substance called 1,3-beta-D-glucan.
How to Take It
Micafungin is given through a vein (IV) by a healthcare provider. The dose depends on your age, weight, and the type of infection. It is usually given once a day, infused slowly over 1 hour. The typical treatment lasts for about 10-20 days.
This is a plain-language summary of micafungin's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
Micafungin may harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. It is not known if micafungin passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding.
This is a plain-language summary of micafungin's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
Since a healthcare provider gives you this medicine, you are not likely to miss a dose. Call your doctor if you think you missed a dose.
This is a plain-language summary of micafungin's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Unopened vials should be stored at room temperature, away from light.
Side Effects (from patient reports)
Based on 4,779 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for micafungin, by number of reports
- Fever
Fever
281 reports
- Fever with low white blood cell count
Fever with low white blood cell count
258 reports
- Failure of multiple organs
Failure of multiple organs
213 reports
- Sudden kidney damage
Sudden kidney damage
204 reports
- Lung failure
Lung failure
193 reports
- Lung infection
Lung infection
190 reports
- Blood infection
Blood infection
187 reports
- Low white blood cell count
Low white blood cell count
176 reports
- Severe blood infection with very low blood pressure
Severe blood infection with very low blood pressure
168 reports
- Diarrhea
Diarrhea
167 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for micafungin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where micafungin sits
micafungin has more FDA adverse-event reports than 25% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is micafungin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 4,779 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
4,779
Reports Mentioning Death
1,712
35.8% of reports — not proof of cause
Hospitalization Reports
2,379
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 3 | PYREXIA | 281 |
| 5 | FEBRILE NEUTROPENIA | 258 |
| 6 | MULTIPLE ORGAN DYSFUNCTION SYNDROME | 213 |
| 7 | ACUTE KIDNEY INJURY | 204 |
| 8 | RESPIRATORY FAILURE | 193 |
| 9 | PNEUMONIA | 190 |
| 10 | SEPSIS | 188 |
| 11 | NEUTROPENIA | 176 |
| 12 | SEPTIC SHOCK | 168 |
| 13 | DIARRHOEA | 167 |
| 14 | CONDITION AGGRAVATED | 163 |
| 15 | CANDIDA INFECTION | 142 |
| 16 | ASPERGILLUS INFECTION | 127 |
| 17 | BRONCHOPULMONARY ASPERGILLOSIS | 127 |
| 18 | DEATH | 127 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Micafungin can cause serious allergic reactions, including shock. Tell your doctor right away if you have hives, trouble breathing, or swelling. It can also cause liver problems. Your doctor will check your liver function during treatment.
Known Drug Interactions
Monitor for sirolimus, itraconazole or nifedipine toxicity, and dosage of sirolimus, itraconazole or nifedipine should be reduced, if necessary. Co-administration of Micafungin for Injection with Other Drugs Co-administration of micafungin for injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin for injection. Nifedipine AUC and C max were increased by 18% and 42%, respectively, in the presence of steady-state micafungin for injection compared with nifedipine alone.
Mechanism: Micafungin increases the amount of nifedipine in your blood by slowing down how your body processes it.
What to do: Your doctor should monitor you for nifedipine side effects and may need to reduce your nifedipine dose.
Co-administration of Micafungin for Injection with Other Drugs Co-administration of micafungin for injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin for injection. 7.2 Effect of Micafungin for Injection on Other Drug CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. Co-administration of Micafungin for Injection with Other Drugs Co-administration of...
Mechanism: These two drugs do not affect how the body breaks down or uses either medication.
What to do: No special dose changes are needed when taking these two drugs at the same time.
(7) 7.1 Effect of Other Drugs on Micafungin for Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of micafungin for injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin for injection. 7.2 Effect of Micafungin for Injection on Other Drug CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. 7.1 Effect of Other Drugs on Micafungin for Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors...
Mechanism: These drugs do not change each other's levels in the bloodstream when taken together.
What to do: You can take these medications together without needing to change your dosage.
(7) 7.1 Effect of Other Drugs on Micafungin for Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of micafungin for injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin for injection. 7.2 Effect of Micafungin for Injection on Other Drug CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. 7.1 Effect of Other Drugs on Micafungin for Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors...
Mechanism: Taking these two drugs together does not change the amount of either drug in your body.
What to do: No dosage adjustments are required when these medications are used together.
CYP2C19 and CYP3A4 Inducer Co-administration of micafungin for injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin for injection. CYP2C19 and CYP3A4 Inducer Co-administration of micafungin for injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin for injection.
Mechanism: Rifampin does not change how the body processes or removes micafungin.
What to do: You do not need to change your micafungin dose if you are also taking rifampin.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
What if I am allergic to other antifungal medicines?
Will micafungin interact with my other medicines?
How long will I need to take micafungin?
What tests will I need while taking micafungin?
Can micafungin cause liver problems?
What should I do if I have side effects?
Can I receive vaccinations while taking micafungin?
Is it safe to drink alcohol while taking micafungin?
How will I know if the medicine is working?
What should I do if my symptoms get worse?
What are the common side effects of micafungin?
Does micafungin interact with other medications?
What drug class is micafungin?
Is micafungin safe during pregnancy?
Has micafungin been recalled?
Active Recalls
Cross contamination with other products
Zydus Pharmaceuticals (USA) Inc
Related Medications in Echinocandin Antifungal
Other drugs grouped near micafungin - same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with micafungin →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with micafungin →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with micafungin →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with micafungin →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with micafungin →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on micafungin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for micafungin
The FDA label for micafungin (sold under brand names such as Mycamine) classifies it as a prescription-only medication in the Echinocandin Antifungal class. Micafungin treats several types of Candida infections. Official labeling lists 8 commonly reported side effects, including Diarrhea, Nausea, Vomiting.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 4,779 voluntary reports. The database also lists 8 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: December 17, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages